| AURINIA PHARMACEUT. |
| Kanada |
| Gesundheit |
| CA05156V1022 / A1W7D4 |
| IKAP (Frankfurt) / AUPH (NASDAQ) |
| FRA:IKAP, ETR:IKAP, IKAP:GR, NASDAQ:AUPH |
| - |
| https://www.auriniapharma.. |
|
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases that have high unmet medical needs. Its flagship product, LUPKYNIS..
>Volltext.. |
| 1610.98 Mio. EUR |
| 1335.55 Mio. EUR |
| 244.6 Mio. EUR |
| 117.13 Mio. EUR |
| 248.18 Mio. EUR |
| 1.87 EUR |
| 64.65 Mio. EUR |
| 69.32 Mio. EUR |
| 117.47 Mio. EUR |
| 4.25 |
| 6.1% |
| 4300.93% |
| - |
| - |
| - |
| AURINIA |
| 23.03.26 |
|